dc.creator | Jiménez Cortegana, Carlos | es |
dc.creator | Palazón Carrión, Natalia | es |
dc.creator | Martín García-Sancho, Alejandro | es |
dc.creator | Nogales-Fernández, Esteban | es |
dc.creator | Carnicero-González, Fernando | es |
dc.creator | Ríos Herranz, Eduardo | es |
dc.creator | Sánchez Margalet, Víctor | es |
dc.creator | Cruz Merino, Luis de la | es |
dc.date.accessioned | 2022-11-15T14:02:06Z | |
dc.date.available | 2022-11-15T14:02:06Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Jiménez Cortegana, C., Palazón-Carrión, N., Martín García-Sancho, A., Nogales-Fernández, E., Carnicero-González, F., Ríos Herranz, E.,...,Cruz Merino, L.d.l. (2021). Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. Journal for Immunotherapy of Cancer, 9 (6), e002323. https://doi.org/10.1136/jitc-2020-002323. | |
dc.identifier.issn | 2051-1426 | es |
dc.identifier.uri | https://hdl.handle.net/11441/139445 | |
dc.description.abstract | Background The search for immunological markers
with ability of predicting clinical outcome is a priority in
lymphomas, and in cancer in general. It is well known
that some immunomodulatory cells, such as myeloid
derived suppressor cells (MDSCs) or regulatory T cells
(Tregs), are recruited by tumors, jeopardizing antitumor
immunosurveillance. In this work, we have studied blood
levels of these immunosuppressive cells in patients with
relapsed/refractory diffuse large B-cell lymphoma (R/R
DLBCL), prior to and along the course of the experimental
rituximab, gemcitabine, dexamethasone, and cisplatin (R2-
GDP) schedule, as a translational substudy of the R2-GDP GOTEL trial (EudraCT Number: 2014-001620-29), which
included lenalidomide as an immunomodulator.
Methods Blood samples were taken before treatment,
at cycle 3 and end of induction. Samples were analyzed
by flow cytometry. Non-parametric tests were used.
Mann-Whitney U test was used to compare basal cells
distributions, and Wilcoxon test was considered to
compare cells distribution at different times. Spearman
test was performed to measure the degree of association
between cell populations.
Results In this study, MDSC and Treg circulating
concentration was found increased in all patients
compared with a healthy control group and decreased
after treatment only in patients with longest overall
survival (>24 months), reaching the levels of the healthy group. Likewise, the number of inhibited T lymphocytes
expressing Programmed Death-1 (PD-1) were increased
in peripheral blood from patients and decreased on the
treatment, whereas activated T lymphocytes increased
after therapy in those with better overall survival.
Conclusions In conclusion, blood concentration of MDSCs
and Treg cells may be good prognostic markers for overall
survival after 2 years in R/R DLBCL. These results point to a
possible role of these elements in the immunosuppression
of these patients, as assessed by the circulating activated
and inhibited T lymphocytes, and therefore, they may be
considered as therapeutic targets in DLBCL. | es |
dc.format | application/pdf | es |
dc.format.extent | 12 p. | es |
dc.language.iso | eng | es |
dc.publisher | BMJ | es |
dc.relation.ispartof | Journal for Immunotherapy of Cancer, 9 (6), e002323. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://jitc.bmj.com/content/9/6/e002323 | es |
dc.identifier.doi | 10.1136/jitc-2020-002323 | es |
dc.journaltitle | Journal for Immunotherapy of Cancer | es |
dc.publication.volumen | 9 | es |
dc.publication.issue | 6 | es |
dc.publication.initialPage | e002323 | es |